ArticleCentral-European journal of immunology2024
Systemic lupus erythematosus in a patient with 22q11.2 deletion syndrome: A case report and review of the literature.
Article in Central-European journal of immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 22q11.2 Deletion Syndrome, Oral-Maxillo-Facial Manifestations and Cognitive Functioning: Three Illustrative Case Reports.Children (Basel, Switzerland) · 2026Article
- DiGeorge Syndrome Complicated by Secondary Antiphospholipid Syndrome Presenting With Vascular Thrombosis.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
22q11.2 deletion syndrome (MIM: 192430/188400, ORPHA: 567) is the most common chromosomal microdeletion disorder, caused by a hemizygous microdeletion of 2.5 million base pairs on chromosome 22. There is a known association between 22q11.2 deletion syndrome (22q11.2DS), immunodeficiency and autoimmune diseases. However, the co-occurrence of 22q11.2DS and systemic lupus erythematosus (SLE) has been rarely reported. Here, we describe a case of a female teenager with distal type I 22q11.2DS who presented with alopecia, oral ulcers, fever and thrombocytopenia. Laboratory tests showed positive antinuclear antibodies (ANA) and double-stranded DNA (ds-DNA) antibodies, indicative of SLE. Treatment with prednisone, hydroxychloroquine and azathioprine resulted in improvement. We reviewed the literature on the immunological mechanisms involved in 22q11.2DS. Thymic dysplasia, T-cell lymphopenia, and B-cell abnormalities collectively contribute to the immunodeficiency and autoimmune manifestations observed in individuals with 22q11.2DS. Genetic factors such as 22q11.2DS should be considered in the diagnosis of childhood rheumatic diseases. Our case adds to the limited literature on this co-occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.